Advertisement

Tumor Biology

, Volume 34, Issue 3, pp 1651–1657 | Cite as

Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk

  • Zhenlong Wang
  • Li Xue
  • Tie Chong
  • Hecheng Li
  • Haiwen Chen
  • Ziming Wang
Research Article

Abstract

Previous studies investigating the association between glutathione S-transferase P1 (GSTP1) Ile105Val polymorphism and bladder cancer risk reported controversial results. This study aimed to quantify the strength of the association between GSTP1 Ile105Val polymorphism and bladder cancer risk by performing a meta-analysis. We searched the PubMed, Embase, and Wanfang databases for publications on the association between GSTP1 Ile105Val polymorphism and bladder cancer risk. We estimated the pooled odds ratios (ORs) with their confidence intervals (95 %CIs) to assess the association. Twenty-five individual studies with a total of 12,360 subjects were finally included. Meta-analysis of all 25 studies showed that GSTP1 Ile105Val polymorphism was associated with increased risk of bladder cancer risk under four genetic comparison models (for G versus A, random-effect OR = 1.19, 95 %CI 1.05–1.35; for GG versus AA, random-effect OR = 1.49, 95 %CI 1.12–1.97; for GG/GA versus AA, random-effect OR = 1.20, 95 %CI 1.03–1.39; for GG versus GA/AA, random-effect OR = 1.41, 95 %CI 1.10–1.80). Sensitivity analysis showed that GSTP1 Ile105Val polymorphism was still associated with bladder cancer risk under three genetic comparison models (for G versus A, random-effects OR = 1.13, 95 %CI 1.01–1.26; for GG versus AA, random-effects OR = 1.29, 95 %CI 1.01–1.65; for GG versus GA/AA, random-effects OR = 1.19, 95 %CI 1.04–1.35). No evidence of publication bias was observed. This meta-analysis shows that there is an obvious association between GSTP1 Ile105ValIle105Val polymorphism and bladder cancer risk, and GSTP1 ILE105VAL polymorphism contributes to bladder cancer risk.

Keywords

Bladder cancer GSTP1 Ile105Val Polymorphism Meta-analysis 

Notes

Conflicts of interest

None.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.PubMedCrossRefGoogle Scholar
  3. 3.
    Sanchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 2012;33:347–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Pandith AA, Siddiqi MA. Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol. 2012;33:1629–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 2009;28:269–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.PubMedCrossRefGoogle Scholar
  7. 7.
    Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, et al. Glutathione S-transferase P1: gene sequence variation and functional genomic studies. Cancer Res. 2008;68:4791–801.PubMedCrossRefGoogle Scholar
  8. 8.
    Ritchie KJ, Walsh S, Sansom OJ, Henderson CJ, Wolf CR. Markedly enhanced colon tumorigenesis in Apc(Min) mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A. 2009;106:20859–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics. 1998;8:27–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19:275–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997;18:641–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics. 1999;9:165–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Steinhoff C, Franke KH, Golka K, Thier R, Romer HC, Rotzel C, et al. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol. 2000;74:521–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, et al. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol. 2001;75:459–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Ma QW, Lin GF, Chen JG, Shen JH. Polymorphism of glutathione S-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci. 2002;15:253–60.PubMedGoogle Scholar
  16. 16.
    Ma Q, Lin G, Qin Y, Lu D, Golka K, Geller F, et al. GSTp1 A1578G (Ile105val) polymorphism in benzidine-exposed workers: an association with cytological grading of exfoliated urothelial cells. Pharmacogenetics. 2003;13:409–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110:598–604.PubMedCrossRefGoogle Scholar
  18. 18.
    Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, et al. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005;104:2400–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, gstm1 null genotype, and risk of bladder cancer: results from the spanish bladder cancer study and meta-analyses. Lancet. 2005;366:649–59.PubMedCrossRefGoogle Scholar
  21. 21.
    Mittal RD, Srivastava DS, A M, B M. Genetic polymorphism of drug metabolizing enzymes (cyp2e1, gstp1) and susceptibility to bladder cancer in north india. Asian Pac J Cancer Prev 2005;6:6–9.Google Scholar
  22. 22.
    Saad AA, O’Connor PJ, Mostafa MH, Metwalli NE, Cooper DP, Povey AC, et al. Glutathione S-transferase M1, T1 and P1 polymorphisms and bladder cancer risk in Egyptians. Int J Biol Markers. 2005;20:69–72.PubMedGoogle Scholar
  23. 23.
    Srivastava DS, Mishra DK, Mandhani A, Mittal B, Kumar A, Mittal RD. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol. 2005;48:339–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Hsu LI, Chiu AW, Huan SK, Chen CL, Wang YH, Hsieh FI, et al. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol. 2008;228:144–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Kopps S, Angeli-Greaves M, Blaszkewicz M, Prager HM, Roemer HC, Lohlein D, et al. Glutathione S-transferase P1 Ile105Val polymorphism in occupationally exposed bladder cancer cases. J Toxicol Environ Health A. 2008;71:898–901.PubMedCrossRefGoogle Scholar
  26. 26.
    Yuan JM, Chan KK, Coetzee GA, Castelao JE, Watson MA, Bell DA, et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis. 2008;29:1386–93.PubMedCrossRefGoogle Scholar
  27. 27.
    Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol. 2009;41:259–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Fontana L, Delort L, Joumard L, Rabiau N, Bosviel R, Satih S, et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res. 2009;29:1631–5.PubMedGoogle Scholar
  29. 29.
    Grando JP, Kuasne H, Losi-Guembarovski R, Sant’ana Rodrigues I, Matsuda HM, Fuganti PE, et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med. 2009;9:21–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Jiang X, Castelao JE, Yuan JM, Groshen S, Stern MC, Conti DV, et al. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis. 2010;31:1964–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Hsu LI, Chen WP, Yang TY, Chen YH, Lo WC, Wang YH, et al. Genetic polymorphisms in glutathione S-transferase (GST) superfamily and risk of arsenic-induced urothelial carcinoma in residents of southwestern Taiwan. J Biomed Sci. 2011;18:51.PubMedCrossRefGoogle Scholar
  32. 32.
    Reszka E, Jablonowski Z, Wieczorek E, Gromadzinska J, Sosnowski M, Wasowicz W. GSTP1 mRNA expression in human circulating blood leukocytes is associated with GSTP1 genetic polymorphism. Clin Biochem. 2011;44:1153–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Safarinejad MR, Safarinejad S, Shafiei N (2011) Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Urol Oncol. doi: 10.1016/j.urolonc.2011.11.027.
  34. 34.
    Zhang R, Xu G, Chen W, Zhang W. Genetic polymorphisms of glutathione S-transferase P1 and bladder cancer susceptibility in a Chinese population. Genet Test Mol Biomarkers. 2011;15:85–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Lesseur C, Gilbert-Diamond D, Andrew AS, Ekstrom RM, Li Z, Kelsey KT, et al. A case–control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire. Toxicol Lett. 2012;210:100–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  37. 37.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  38. 38.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  39. 39.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  40. 40.
    Thompson SG, Higgins J. How should meta–regression analyses be undertaken and interpreted? Statistics in medicine. 2002;21:1559–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.Google Scholar
  42. 42.
    Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.PubMedCrossRefGoogle Scholar
  43. 43.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  44. 44.
    Chang J, Dinney CP, Huang M, Wu X, Gu J. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One. 2012;7:e30665.PubMedCrossRefGoogle Scholar
  45. 45.
    Gong M, Dong W, An R. Glutathione S-transferase T1 polymorphism contributes to bladder cancer risk: a meta-analysis involving 50 studies. DNA Cell Biol. 2012;31:1187–97.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2012. doi: 10.1007/s13277-012-0633-7.
  47. 47.
    Cahill LE, Fontaine-Bisson B, El-Sohemy A. Functional genetic variants of glutathione S-transferase protect against serum ascorbic acid deficiency. Am J Clin Nutr. 2009;90:1411–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Zhenlong Wang
    • 1
  • Li Xue
    • 1
  • Tie Chong
    • 1
  • Hecheng Li
    • 1
  • Haiwen Chen
    • 1
  • Ziming Wang
    • 1
  1. 1.Department of Urology, Second Affiliated Hospital, School of MedicineXi’an Jiaotong UniversityXi’anChina

Personalised recommendations